Indole, a core nucleus for potent inhibitors of tubulin polymerization

Microtubules are the basic components of cell structure, which take part in a wide number of pivotal cellular functions. Drugs that are able to modulate the microtubule assembly either by inhibition of tubulin polymerization or by blocking microtubule disassembly are of great interest in anti‐cancer therapy. Several tubulin polymerization inhibitors characterized by the presence of an indole nucleus have been obtained from natural sources or have been prepared by semi‐synthesis. In the last decade an ever increasing number of synthetic indoles have been reported. We have reviewed anti‐tubulin agents obtained by synthesis having an indole as core nucleus. The synthesis, the biological activity, and the structure–activity relationship aspects of 3‐formyl‐2‐phenylindoles, heterocombretastatins, diarylindoles, 2‐aroylindoles, D‐24851, 2‐aryl‐3‐aroylindoles, 3‐aroyl‐ and 1‐aroylindoles, and arylthioindoles are discussed. © 2006 Wiley Periodicals, Inc. Med Res Rev

[1]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[2]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[3]  H. Morita,et al.  Antimitotic activity of moroidin, a bicyclic peptide from the seeds of Celosia argentea. , 2000, Bioorganic & medicinal chemistry letters.

[4]  H. Prinz.  Recent advances in the field of tubulin polymerization inhibitors , 2002, Expert review of anticancer therapy.

[5]  J. Barret,et al.  Novel aspects of natural and modified vinca alkaloids. , 2012, Current medicinal chemistry. Anti-cancer agents.

[6]  D. Covell,et al.  Antimitotic peptides and depsipeptides. , 2012, Current medicinal chemistry. Anti-cancer agents.

[7]  H. Morita,et al.  Celogentins A-C, new antimitotic bicyclic peptides from the seeds of Celosia argentea. , 2001, The Journal of organic chemistry.

[8]  T. Macdonald,et al.  Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. , 2002, Journal of medicinal chemistry.

[9]  Andrea Brancale,et al.  Arylthioindoles, potent inhibitors of tubulin polymerization. , 2004, Journal of medicinal chemistry.

[10]  H. Hsieh,et al.  Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. , 2004, Journal of medicinal chemistry.

[11]  H. Sham,et al.  Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer , 2002 .

[12]  H. Rosenkranz,et al.  Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. , 1996, Bioorganic & medicinal chemistry.

[13]  G. Storme,et al.  Phase I trial of erbulozole (R55104). , 1993, Anticancer Research.

[14]  I. Paterson,et al.  A practical synthesis of (+)-discodermolide and analogues: fragment union by complex aldol reactions. , 2001, Journal of the American Chemical Society.

[15]  S. Cacchi,et al.  2-Substituted-3-acylindoles through the Palladium-Catalysed Carbonylative Cyclization of 2-Alkynyltrifluoroacetanilides with Aryl Halides and Vinyl Triflates , 1994 .

[16]  R. D'Amato,et al.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Hamel,et al.  Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. , 1989, Biochemistry.

[18]  Andrea Brancale,et al.  New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. , 2006, Journal of medicinal chemistry.

[19]  E. Caballero,et al.  Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. , 1999, Bioorganic & medicinal chemistry letters.

[20]  A. Mannschreck,et al.  Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives. , 1997, Journal of medicinal chemistry.

[21]  G. Burton,et al.  An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. , 2006, Bioorganic & medicinal chemistry letters.

[22]  T. Beckers,et al.  Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. , 2001, Journal of medicinal chemistry.

[23]  Arcadi Antonio,et al.  A versatile approach to 2,3-disubstituted indoles through the palladium-catalysed cyclization of o-alkynyltrifluoroacetanilides with vinyl triflates and aryl halides , 1992 .

[24]  T. Beckers,et al.  Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy , 2003 .

[25]  D. Marko,et al.  Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. , 1998, Journal of medicinal chemistry.

[26]  T. Mayumi,et al.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly. , 1998, The Biochemical journal.

[27]  A. Owens,et al.  The binding of vincristine, vinblastine and colchicine to tubulin. , 1972, Biochemical and biophysical research communications.

[28]  B. Hill,et al.  Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. , 2001, Critical reviews in oncology/hematology.

[29]  H. Reichenbach,et al.  Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution† , 1996 .

[30]  A. Yamaguchi,et al.  Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.

[31]  E. Hamel,et al.  Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. , 1983, Biochemical pharmacology.

[32]  S Seeber,et al.  D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. , 2001, Cancer research.

[33]  H. Rosenkranz,et al.  Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. , 1996, Biochemistry.

[34]  J. Jaén,et al.  Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Renard,et al.  Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. , 2001, Bioorganic & medicinal chemistry letters.

[36]  Richard E. Moore,et al.  Laulimalides. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator , 1988 .

[37]  P. Hamel,et al.  A New Synthesis of 3-Arylthioindoles , 1988 .

[38]  A. Yoshimura,et al.  Phase I study of E7010 , 1998, Cancer Chemotherapy and Pharmacology.

[39]  David J Newman,et al.  A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. , 2004, Journal of natural products.

[40]  D. Kingston,et al.  The chemistry of taxol. , 1991, Pharmacology & therapeutics.

[41]  S. Tamai,et al.  Current Status of Oral Carbapenem Development , 2002 .

[42]  E. Nogales,et al.  Tubulin and microtubule structure , 1998 .

[43]  E Hamel,et al.  The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. , 2001, Bioorganic & medicinal chemistry letters.

[44]  R. Williamson,et al.  Synthesis and biological activity of analogues of the antimicrotubule agent N, β, β-trimethyl-L-phenylalanyl-N1-[(1S, 2E)-3-carboxy-1-isopropylbut-2-enyl]-N1, 3 -dimethyl-L-valinamide (HTI-286) , 2004 .

[45]  P. Renard,et al.  Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. , 2004, Journal of medicinal chemistry.

[46]  H. Hsieh,et al.  BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo , 2004, Cancer Research.

[47]  E. Hamel,et al.  One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. , 2002, Journal of medicinal chemistry.

[48]  E. Caballero,et al.  Synthesis and antineoplastic activity of combretastatin analogues: Heterocombretastatins , 1998 .

[49]  R. C.-Gaudreault,et al.  Antimitotic antitumor agents: synthesis, structure-activity relationships, and biological characterization of N-aryl-N'-(2-chloroethyl)ureas as new selective alkylating agents. , 2001, Journal of Medicinal Chemistry.

[50]  U. Vanhoefer,et al.  2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. , 2002, Cancer research.

[51]  H. Hsieh,et al.  Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. , 2004, Journal of medicinal chemistry.

[52]  William Fenical,et al.  Isolation and Structure Determination of Diazonamides A and B, Unusual Cytotoxic Metabolites from the Marine Ascidian Diazona chinensis , 1991 .

[53]  E. Hamel,et al.  Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. , 1988, Molecular pharmacology.